Drug Trial Radar · NCT00571675
A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Last checked: Nov 19, 2026Latest source record: Nov 9, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
220
Actual
Start
Oct 2007
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Ascenta TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled, multinational Phase 2 study to evaluate and compare oral AT-101 in combination with docetaxel and prednisone versus docetaxel and prednisone plus placebo in the treatment of chemotherapy-naïve metastatic hormone-refractory prostate cancer, who have received hormonal therapy but not chemotherapy.
Conditions
- Hormone Refractory Prostate Cancer
Interventions
AT-101, prednisone and docetaxelDrug
docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
placebo, prednisone and docetaxelDrug
docetaxel (75mg/m2 intravenously over 1 hour every 21 days \[one cycle\]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate and compare the two treatment arms with respect to overall survival (OS)Time frame: 33 months
Locations
35 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Colorado Springs, Colorado
Site not named
New Port Richey, Florida
Site not named
Ocoee, Florida
Site not named
Fishers, Indiana
Site not named
Burnsville, Minnesota
Site not named
Las Vegas, Nevada
Site not named
Albuquerque, New Mexico
Site not named
Las Cruces, New Mexico
Site not named
Raleigh, North Carolina
Site not named
Kettering, Ohio
Site not named
Eugene, Oregon
Site not named
Spartanburg, South Carolina
Site not named
Amarillo, Texas
Site not named
Arlington, Texas
Site not named
Austin, Texas
Site not named
Dallas, Texas
Site not named
Denton, Texas
Site not named
Midland, Texas
Site not named
Paris, Texas
Site not named
Webster, Texas
Site not named
Fairfax, Virginia
Site not named
Norfolk, Virginia
Site not named
Kennewick, Washington
Site not named
Vancouver, Washington
Site not named
Barnaul, Russia
Site not named
Engel's, Russia
Site not named
Kazan', Russia
Site not named
Kursk, Russia
Site not named
Kuzmolovsky, Russia
Site not named
Moscow, Russia
Site not named
Saint Petersburg, Russia
Site not named
Sochi, Russia
Site not named
Stavropol, Russia
Site not named
Voronezh, Russia
Site not named
Yekaterinburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.